For the delivery of a range of DMPK services
Selvita, a Polish provider of drug discovery services, has entered an agreement with Evestra, the German subsidiary of Evestra Inc, to deliver a range of drug metabolism, pharmacokinetic (DMPK) and physicochemical studies.
Under the contract, the firms will work on drug metabolism and pharmacokinetics studies, including CYP inhibition, metabolic identification and stability.
The project will also involve oral bioavailability and pharmacokinetics assays, both in vitro and in vivo, accompanied by gentotoxicity testing.
Dr Milosz Gruca, head of Selvita’s biology department, said Evestra’s decision to entrust Selvita with this project gives its research team a chance to show their potential and capabilities to run complex projects in yet another field of preclinical research.